Latest Animal And Human Health News

Vitrafy Life Sciences reported robust progress in Q4 FY2025, advancing its cryopreservation technology and commercial partnerships while preparing for a pivotal product launch in FY2026.

Vitrafy Life Sciences reported a dramatic increase in half-year losses to $25.7 million, yet successfully raised $35 million through an IPO to fuel its cryopreservation technology expansion.

Vitrafy Life Sciences reports strong Q2 FY2025 progress, marked by a successful $35 million IPO, promising validation results in animal and human health, and strategic expansion into North America.